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Background. Acute otitis media (AOM) is a common diagnosis in outpatient pediatrics that often results in antibiotic prescriptions. In 2013, revised clinical practice guidelines for AOM by the American Academy of Pediatrics (AAP) recommended reserving antibiotics and a watchful waiting (WW) approach in most scenarios; amoxicillin ±clavu-lanate as first-line agents if treating; and courses of >7 days to be clearly indicated only in severe cases in those ≤2 years old. Adherence to AOM guidelines amongst pediatric providers, especially in nonacademic outpatient settings, has not been well characterized.
Methods. In a large community-based sepsis point prevalence study, diagnosis, antibiotic prescription, and other data were collected from all patients aged 0 to 18 years seen on September 5, 2016 , December 5, 2016 , March 6, 2017 , and June 5, 2017 , in the Emergency Department (ED) of the Women and Children's Hospital of Buffalo, 11 primary pediatric (PMD) offices, and 2 private urgent care centers (UCC) in Buffalo, NY. For this secondary analysis, all children with a provider diagnosis of acute otitis media (AOM) were identified. Adherence to AAP AOM guidelines were analyzed and compared relative to clinical care setting.
Results. Of 2,062 sick visits, 6% (121) were diagnosed with AOM, and in 82% of these antibiotics were prescribed: 91% (39/43) in ED; 70% (21/30) in UCC; 83% (40/48) in PMD, P = 0.071. When prescribed, 69% of antibiotics were first-line agents. In UCC and PMD, oral third-generation cephalosporins were the most common nonfirst-line agents, followed by azithromycin (20% and 8% of all antibiotic prescribed cases respectively). Ninety percent of antibiotic courses were ≥7 days. There were no differences in prescribing practices between outpatient settings Conclusion. A recent study found that WW is clinically appropriate in >50% of pediatric AOM and overall cost-effective. However, in our analysis, antibiotics are still being prescribed in four out of five cases. Non-first-line agents, which are excessively broad and/ or suboptimal in targeting the main pathogens for pediatric AOM, are given in over a quarter of prescriptions. Increasing awareness and adherence to AOM guidelines, in various outpatient settings, should be a major target of pediatric antibiotic stewardship efforts.
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Background. Outpatient parenteral antimicrobial therapy (OPAT) has shifted from being a novel concept to an accepted model of care for some conditions. However, concerns remain that have limited its broader roll out: the use of daily ceftriaxone regarding its efficacy and impact on antibiotic resistance, intravenous (IV) catheter complications, risk of treating an acute infection directly from the emergency room (ER), and concern that OPAT has shifted the burden of cost from hospitals to patients. We aimed to address these questions with the first randomized controlled trial (RCT) of OPAT efficacy in children: comparing OPAT directly from the ER using IV ceftriaxone with hospitalization using IV flucloxacillin for moderate/severe cellulitis.
Methods. The RCT was set at a tertiary pediatric hospital from January 2015 to June 2017. Inclusion criteria: children 6 months-18 years with uncomplicated cellulitis needing IV antibiotics. Patients were randomized to ceftriaxone via OPAT at home or flucloxacillin in hospital, using a peripheral catheter. Primary outcome: treatment failure within 48 hours due to lack of improvement or adverse events. Secondary outcomes: complications, readmission, acquisition of nasal and stool-resistant bacteria and costs.
Results. A total of 188 children were randomized: 93 to OPAT and 95 to hospital. In the intention-to-treat population, there was no difference in treatment failure between OPAT and hospital (2% vs. 7%, P = 0.09). Per protocol, OPAT had less failure (1% vs. 8%, P = 0.03). There was no increased acquisition of MRSA, ESBL, VRE or C. difficile with OPAT compared with in hospital at 1 week or 3 months (P > 0.05). Complication rates were similar (6% vs. 7%, P = 0.78), and repeat IV catheterization was less with OPAT (3% vs. 15%, P = 0.002). Readmission was 1% on OPAT. The cost to families was significantly less with OPAT (AUD213 vs. AUD733, P < 0.001).
Conclusion. Despite the acuity of the infection, OPAT with IV ceftriaxone for moderate/severe cellulitis in children is efficacious with complications and readmissions no different from hospital care with IV flucloxacillin. Short-term ceftriaxone use in healthy children on OPAT is not associated with increased acquisition of resistant organisms, and has reduced burden of costs to families (ClinicalTrials.gov NCT02334124).
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